Lucid Diagnostics Announces Data From The First Prospective Clinical Validation Study Of EsoGuard Esophageal Precancer Testing In A Screening Population
Portfolio Pulse from Benzinga Newsdesk
Lucid Diagnostics Inc. (LUCD) and its majority-owned parent company PAVmed Inc. (PAVM) announced positive results from the first prospective clinical validation study of EsoGuard, a test for esophageal precancer detection. Conducted at the Louis Stokes Cleveland Veterans Affairs Medical Center, the study showed EsoGuard's sensitivity at 92.9% and negative predictive value at 98.6%. These results, along with previous studies, support EsoGuard's use as a screening tool for esophageal precancer and cancer, potentially leading to broader medical policy coverage and CMS coverage.
March 21, 2024 | 1:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Lucid Diagnostics announced promising results from a clinical study of EsoGuard, showing high sensitivity and negative predictive value for esophageal precancer detection. This could lead to broader adoption and insurance coverage.
The positive clinical validation study results for EsoGuard directly impact Lucid Diagnostics by potentially increasing the test's adoption and insurance coverage, which could lead to higher revenues and market penetration for LUCD.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
PAVmed, as the majority owner of Lucid Diagnostics, stands to benefit from the positive clinical study results of EsoGuard, potentially leading to increased value from its subsidiary.
PAVmed's majority ownership in Lucid Diagnostics means that positive developments for Lucid, such as the promising EsoGuard study results, could positively impact PAVmed's valuation and financial outlook.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 80